Richard C. Zellars, MD, talks with Jean Wright, MD, about the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial, which evaluated the impact of tamoxifen only after breast conservation surgery for “good risk” ductal carcinoma in situ.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: